All In Biotech

Drug Trial Radar · NCT03237325

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

Last checked: Nov 20, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 266 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

266

Actual

Start

Dec 4, 2017

Primary completion

Jun 24, 2020

Study completion Jun 24, 2021

Sponsor

Lead sponsor
SoligenixIndustry
Sponsor type
Industry
First posted
Aug 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer

Conditions

  • Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
  • Oral Mucositis

Interventions

  • SGX942Drug

    1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.

  • PlaceboDrug

    Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of Severe Oral Mucositis (SOM)Time frame: approx. 13 weeks

Locations

53 sites in 5 countries. Site status is shown where the registry gives one.

  • Arizona Clinical Research Center

    Tucson, Arizona

  • Loma Linda University Health

    Loma Linda, California

  • Pomona Valley Hospital Medical Center

    Pomona, California

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Lakes Research

    Miami Lakes, Florida

  • University Cancer & Blood

    Athens, Georgia

  • Augusta University

    Augusta, Georgia

  • Memorial Health

    Savannah, Georgia

  • University of Illinois Cancer Center

    Chicago, Illinois

  • Carle Cancer Center

    Urbana, Illinois

  • Des Moines Oncology Research Association

    Des Moines, Iowa

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Ashland Bellefonte Cancer Center

    Ashland, Kentucky

  • Willis Knighton Cancer Center

    Shreveport, Louisiana

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Minnesota Oncology

    Saint Louis Park, Minnesota

  • University of Missouri-Ellis Fischel Cancer Center

    Columbia, Missouri

  • Great Falls Clinic

    Great Falls, Montana

  • CHI Health St. Francis

    Grand Island, Nebraska

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada

  • Nevada Cancer Research Foundation

    Las Vegas, Nevada

  • Hackensack Meridian Health

    Neptune City, New Jersey

  • University of Rochester

    Rochester, New York

  • Summa Health Cancer Research

    Akron, Ohio

  • The Christ Hospital

    Cincinnati, Ohio

  • Mercy Clinic Oncology and Hematology

    Oklahoma City, Oklahoma

  • Oklahoma Cancer Specialists

    Tulsa, Oklahoma

  • Charleston Cancer Center

    Charleston, South Carolina

  • Spartanburg Regional-Gibbs Cancer Center

    Spartanburg, South Carolina

  • University of Virginia

    Charlottesville, Virginia

  • Providence Regional Cancer Partnership

    Everett, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Universitair Ziekenhuis Antwerpen

    Antwerp, Belgium

  • Centre Hospitalier Jolimont

    La Louvière, Belgium

  • Centre Hospitalier Universitaire de Mons

    Mons, Belgium

  • CFRO Clinique Pasteur

    Brest, France

  • Institut Andrée Dutreix

    Dunkirk, France

  • Clinique Victor Hugo

    Le Mans, France

  • Hôpital de la Croix Rousse

    Lyon, France

  • CROM-Osny

    Osny, France

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.